EU/3/03/155: Orphan designation for the treatment of ovarian cancer

Murine anti-idiotypic antibody against OC125 antibody against CA125 antigen

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2012 on request of the sponsor.

On 9 July 2003, orphan designation (EU/3/03/155) was granted by the European Commission to Cell Control Biomedical Laboratories AG, Germany, for murine anti-idiotypic antibody against OC125 antibody against CA125 antigen (ACA125) for the treatment of ovarian cancer.

The sponsorship was transferred to Menarini Ricerche S.p.A. in December 2004.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Murine anti-idiotypic antibody against OC125 antibody against CA125 antigen
Intended use
Treatment of ovarian cancer
Orphan designation status
Withdrawn
EU designation number
EU/3/03/155
Date of designation
09/07/2003
Sponsor
Menarini Ricerche S.p.A.
Via Tito Speri 10
00040 Pomezia (Roma)
Italy
Tel: +39 05 55 68 03 13
Fax +39 05 55 68 09 95 4
E-mail: abagovomab@menarini-ricerche.it

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating